Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes

• Status: Completed
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will compare plasma kinetics of two marker drugs in individuals with different genetic variations in the MDR1-gene. The hypothesis is that one group will have higher exposure than the other.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Karolinska Institutet
• Treatments: Digoxin; Fluvoxamine

Criteria

Inclusion Criteria:

• - Healthy volunteer ≥ 18 years of age

• Normal kidney function as measured by GFR according to Cockroft-Gault (70-120 ml/min)

• Normal P-potassiumvalue (3,6-4,6 mmol/L)

• HF>50 and no AV-block on resting ECG. No other significant abnormalities as judged by the investigator.

• Subject giving written informed consent

• Subject capable of understanding instructions

Exclusion Criteria:

• - Pregnancy

• Ongoing infection

• Intake of medication, including natural remedies (for example St John´s wort), within one month prior to starting study except for paracetamol.

• Active drug or alcohol abuse